Revvity (NYSE:RVTY) Stock Price Target Raised at JPMorgan Chase & Co.

Key Points

• JPMorgan raised Revvity’s price target from $155 to $160 but kept a neutral rating; the target implied 1.51% downside from the prior close.
• Revvity beat quarterly estimates, reporting adjusted EPS of $1.38 and revenue of $728.9 million, up 4.3% year over year; the company also raised its 2026 outlook.
• Analyst views remain mixed but skew toward Hold: MarketBeat cited six Buy ratings and 13 Hold ratings, with a consensus target of $133.86.

Revvity (NYSE:RVTY - Get Free Report) had its price objective raised by equities researchers at JPMorgan Chase & Co. from $155.00 to $160.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s price objective would suggest a potential downside of 1.51% from the company's previous close.

A number of other research firms have also recently commented on RVTY. Barclays lifted their target price on shares of Revvity from $160.00 to $175.00 and gave the stock an "equal weight" rating in a research note on Wednesday. Wall Street Zen lowered shares of Revvity from a "buy" rating to a "hold" rating in a research note on Sunday, August 16th. Bank of America reaffirmed a "neutral" rating on shares of Revvity in a report on Wednesday. TD Cowen lifted their price objective on shares of Revvity from $175.00 to $185.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, William Blair started coverage on shares of Revvity in a report on Monday, October 5th. They set an "outperform" rating on the stock. Six analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $133.86.

Revvity Stock Down 0.6%

NYSE:RVTY traded down $1.02 during mid-day trading on Wednesday, hitting $162.46. 1,684,210 shares of the company's stock traded hands, compared to its average volume of 1,536,434. The company has a fifty day moving average of $145.89 and a 200 day moving average of $112.62. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. Revvity has a twelve month low of $81.22 and a twelve month high of $171.74. The company has a market capitalization of $18.13 billion, a P/E ratio of 77.20, a P/E/G ratio of 2.76 and a beta of 1.08.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.08. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The business had revenue of $728.90 million during the quarter, compared to the consensus estimate of $694.73 million. During the same quarter last year, the company earned $1.18 earnings per share. The company's quarterly revenue was up 4.3% on a year-over-year basis. On average, analysts forecast that Revvity will post 5.36 EPS for the current year.

Insider Activity at Revvity

In other Revvity news, insider Tajinder Vohra sold 7,330 shares of the firm's stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the transaction, the insider directly owned 6,635 shares of the company's stock, valued at approximately $934,738.80. This trade represents a 52.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Maxwell Krakowiak sold 1,631 shares of the firm's stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the transaction, the insider directly owned 14,781 shares of the company's stock, valued at $2,136,297.93. This represents a 9.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 9,045 shares of company stock worth $1,281,439. 0.85% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RVTY. Jupiter Topco LLC acquired a new stake in Revvity in the second quarter valued at approximately $961,017,000. BlackRock Inc. acquired a new position in shares of Revvity during the 2nd quarter worth approximately $852,070,000. EdgePoint Investment Group Inc. raised its stake in shares of Revvity by 3.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company's stock worth $771,044,000 after buying an additional 265,204 shares during the period. Janus Henderson Group PLC raised its stake in shares of Revvity by 2.3% during the 1st quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company's stock worth $731,386,000 after buying an additional 186,956 shares during the period. Finally, State Street Corp lifted its position in shares of Revvity by 0.8% during the 2nd quarter. State Street Corp now owns 4,342,739 shares of the company's stock valued at $483,173,000 after buying an additional 32,426 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company's stock.

Revvity News Roundup

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported Q3 adjusted EPS of $1.38, above the roughly $1.30 consensus, and revenue of $728.9 million versus estimates of about $694.7 million. Revenue grew 4.3% year over year, with Life Sciences strength and margin expansion contributing to the beat. The company also raised its 2026 outlook. Q3 earnings beat and outlook
• Positive Sentiment: CFRA upgraded RVTY from Hold to Buy, adding a favorable analyst view after the results. CFRA upgrade
• Neutral Sentiment: Royal Bank of Canada raised its price target from $135 to $172 but retained a Sector Perform rating; the new target implied about 6.3% upside at the cited share price. RBC price target
• Neutral Sentiment: Some coverage questioned whether the stock is now expensive after its earnings-driven run. That concern may limit further gains, particularly given the high valuation noted in the provided market data. Dividend and valuation discussion

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.